title: Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis.
abstract: We performed a meta-analysis to evaluate the risk of venous thromboembolism (VTE) in pregnant women with essential thrombocythemia. Twenty-one trials and 756 pregnancies met inclusion criteria. The absolute VTE risk in the antepartum period is not above a threshold where low-molecular-weight heparin (LMWH) prophylaxis is clearly indicated or below a threshold where LMWH should be withheld (2.5%; 95% CI, 1.3-4.3). Postpartum, the absolute VTE risk is above a threshold where postpartum LMWH prophylaxis should be considered (4.4%; 95% CI, 1.2-9.5).
authors.affiliation: Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
authors.forename: Leslie
authors.identifier: 0000-0002-5587-398X
authors.initials: L
authors.lastname: Skeith
authors.affiliation: Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.|Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
authors.forename: Marc
authors.initials: M
authors.lastname: Carrier
authors.affiliation: Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom; and.
authors.forename: Susan E
authors.initials: SE
authors.lastname: Robinson
authors.affiliation: Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom; and.
authors.forename: Samah
authors.initials: S
authors.lastname: Alimam
authors.affiliation: Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.|Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.|Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, ON, Canada.
authors.forename: Marc A
authors.identifier: 0000-0001-8166-3487
authors.initials: MA
authors.lastname: Rodger
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D049590:Postpartum Period / Q000187:drug effects; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000209:etiology* / Q000517:prevention & control*; D012306:Risk; D013920:Thrombocythemia, Essential / Q000150:complications*; D054556:Venous Thromboembolism / Q000209:etiology* / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight